Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 13/20 | 0.73 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.73 |
| ▸ | NQO2 | P16083 | 7/20 | 0.73 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16192287 | 1.00 | PTGS1 (0.73) | PTGS1PTGS2NQO2ESR1ESR2 | |
| SCHEMBL16191734 | 0.87 | PTGS1 (0.70) | PTGS1PTGS2NQO2ALOX5 | |
| SCHEMBL16191732 | 0.87 | PTGS1 (0.70) | PTGS1PTGS2NQO2ALOX5 | |
| SCHEMBL3811776 | 0.83 | PTGS1 (0.75) | PTGS1PTGS2NQO2ESR1ESR2 | |
| SCHEMBL3811778 | 0.83 | PTGS1 (0.75) | PTGS1PTGS2NQO2ESR1ESR2 | |
| SCHEMBL16307444 | 0.79 | PTGS1 (0.59) | PTGS1PTGS2NQO2ALOX5 | |
| SCHEMBL10365751 | 0.77 | PTGS1 (0.56) | PTGS1PTGS2NQO2ESR1CA5A | |
| SCHEMBL2182990 | 0.74 | PTGS1 (0.70) | PTGS1PTGS2NQO2ESR1ESR2 | |
| SCHEMBL2182986 | 0.74 | PTGS1 (0.70) | PTGS1PTGS2NQO2ESR1ESR2 | |
| SCHEMBL8827308 | 0.71 | PTGS1 (0.46) | PTGS1PTGS2NQO2ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2796442-B1 | CAJANINE STRUCTURE ANALOGOUS COMPOUND, PREPARATION METHOD AND USE | INST MED BIOTECHNOLOGY CAMS (CN) | 2019-03-27 | — | — | EP | disclosed |
| EP-2796442-B1 | CAJANINE STRUCTURE ANALOGOUS COMPOUND, PREPARATION METHOD AND USE | INST MED BIOTECHNOLOGY CAMS (CN) | 2019-03-27 | — | — | EP | disclosed |
| US-9359298-B2 | Cajanine structure analogous compound, preparation method and use | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2016-06-07 | — | — | US | disclosed |
| US-9359298-B2 | Cajanine structure analogous compound, preparation method and use | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2016-06-07 | — | — | US | disclosed |
| US-9359298-B2 | Cajanine structure analogous compound, preparation method and use | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2016-06-07 | — | — | US | disclosed |
| US-20140371232-A1 | CAJANINE STRUCTURE ANALOGOUS COMPOUND, PREPARATION METHOD AND USE | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2014-12-18 | — | — | US | disclosed |
| US-20140371232-A1 | CAJANINE STRUCTURE ANALOGOUS COMPOUND, PREPARATION METHOD AND USE | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2014-12-18 | — | — | US | disclosed |
| US-20140371232-A1 | CAJANINE STRUCTURE ANALOGOUS COMPOUND, PREPARATION METHOD AND USE | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2014-12-18 | — | — | US | disclosed |
| EP-2796442-A1 | CAJANINE STRUCTURE ANALOGOUS COMPOUND, PREPARATION METHOD AND USE | Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (CN) | 2014-10-29 | — | — | EP | disclosed |
| EP-2796442-A1 | CAJANINE STRUCTURE ANALOGOUS COMPOUND, PREPARATION METHOD AND USE | Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (CN) | 2014-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371232-A1 | CAJANINE STRUCTURE ANALOGOUS COMPOUND, PREPARATION METHOD AND USE | ACHE, GAP43, LNPK | PTGS1 2474/4885PTGS2 3230/4885NQO2 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.